drugset / Trial / NCT01879917
Liraglutide in Newly Onset Type 1 Diabetes.
Phase 2/3
Completed
65 enrolled
Hvidovre University Hospital
Aalborg University Hospital · collabAarhus University Hospital · collabBispebjerg Hospital · collabEsbjerg Hospital - University Hospital of Southern Denmark · collabHillerod Hospital, Denmark · collabOdense University Hospital · collabSteno Diabetes Center Copenhagen · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to investigate the effect and safety of liraglutide 1.8 mg once daily compared to placebo for 52 weeks on change in beta-cell function in patients with newly diagnosed type 1 diabetes as an adjunctive therapy to insulin treatment.
Timeline
- Start
- 2014-02
- Primary completion
- 2018-08
- Completion
- 2018-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Liraglutide | Peptide | 1.8 mg | — |